Abbott (NYSE: ABT) and BG Medicine, Inc. announced a development and commercialization agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression of heart failure. The assay will be developed for Abbott’s ARCHITECT immunochemistry instrument platform, specifically the company’s i1000SR and i2000SR instruments. The agreement grants Abbott a [...]

Susan Taylor, Ph.D., whose research has advanced understanding of how proteins are regulated in the body, has been awarded the 2009 Vanderbilt Prize in Biomedical Science.
The prize, established by the Vanderbilt University School of Medicine in 2006, honors women who have made significant advances in the biological and biomedical sciences and have contributed positively to [...]

AstraZeneca is to double its investment in Cancer Research UK’s biomarker research in an effort to better understand how drugs behave in early stage clinical trials.
This announcement coincides with a presentation at the NCRI Cancer Conference in Birmingham by Professor Caroline Dive from Cancer Research UK’s Paterson Institute for Cancer Research at the University [...]

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Fred Schnell of AVI presented at the American Society of Virology Annual Meeting which took place July 11-15 in Vancouver, B.C. The title of the presentation was “Pan-Arenavirus Antisense Therapeutic Based On PMOplus™ Chemistry.” In addition to Dr. Schnell, Drs. Bestwick, [...]

Dr. Reddy’s announced that the first human subjects were successfully dosed in a phase I study with DRL 17822, a selective inhibitor of CETP, for the treatment of dyslipidemia, atherosclerosis and associated cardiovascular diseases. The compound shows potent elevation in HDL-C and reduction of atherosclerotic plaques in animals, and has a clean safety profile in [...]